Effect of neoadjuvant therapy on tumor size reduction in breast cancer

The study is carried out as retrospective and prospective observational studies to analyze the cancer characteristics, therapeutic approaches and the state of depression in Breast cancer patients. Breast cancer is one of the highly prevalent female specific carcinomas, however, the rarity of male breast cancers is observed. Neoadjuvant chemotherapy (NAC) has been shown to be a useful strategy in the treatment of Locally advanced breast cancer (LABC) because it results in tumor downstaging benefits. This study agrees with what Chintamani et al. found in India in a study population with similar characteristics and the same chemotherapy regimen. Neoadjuvant chemotherapy has proved appealing potential benefits over the classic adjuvant therapy. Apart from cancer characteristics and therapeutic statistics, the effects of Doxorubicin neoadjuvant therapy were analyzed with respect to tumor size after each cycle of NAC. The significant change in the tumor size (measured in cm) of 39 patients undergoing NAC. The use of Doxorubicin for neoadjuvant therapy was found to be significantly beneficial in the reduction of tumor size of locally advanced breast cancers (LABC). This reduction in tumor size prior surgery helps in the choice of type of surgery being performed. It can result in avoiding the use of mastectomy and more preference for breast-conserving surgeries can be given.